Navigation Links
GenTel gets federal grant to develop allergy test

Madison, Wis. - GenTel BioSciences, Inc., a developer of protein chip technologies, has received a $1.2 million Phase II SBIR grant from the National Institutes of Health to develop a test that promises less painful diagnosis of respiratory allergies.

An estimated 50 million Americans suffer from mild to chronic seasonal allergies, and current d......

Full article >>> rovide sizeable amounts of blood and have a slow turnaround time for results, so a small prick of the finger involved in the new test is preferred over both existing methods.

Vodenlich said the company's biochips provide a more qualitative and quantitative way to measure how allergic patients are to certain allergens, which would be a leap forward in allergy diagnosis. GenTel has the all......

Full article >>> A key collaborator on the allergy project is Dr. Robert K. Bush, a professor of medicine at University of Wisconsin-Madison School of Medicine and Public Health. "What our company is all about right now is developing biochip tests that are going to be used in research," Vodenlich said. "The nice thing about the allergy chip is that it will first be used in research and validated by allergists like......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 05/22/06


Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. New angel capital centered on GenTel agreement with big pharma
3. GenTel licenses next generation cancer research
4. GenTel to distribute cancer research tool
5. Madisons GenTel partners with Taiwan firm
6. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
7. GenTel BioSurfaces launches new assay platform
8. GenTel will sell Dutch firms biomolecule labeling technology
9. Bone Care, GenTel, MyWeather
10. GenTel receives $250,000 state loan
11. GenTel claims $900,000 in federal grants this year for biochip research
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... FL (PRWEB) , ... October ... ... (RPS®) today announces publication of a United States multicenter, prospective clinical study ... use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
Breaking Biology News(10 mins):